{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:36:16Z","timestamp":1753180576390,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The study investigates the prognostic significance of beta-blocker (BB) dose in patients with ventricular tachyarrhythmias. Limited data regarding the prognostic impact of BB dose in ventricular tachyarrhythmias is available. A large retrospective registry was used including consecutive patients on BB treatment with episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2015. Discharge BB doses were grouped as\u2009&gt;\u20090\u201312.5%,\u2009&gt;\u200912.5\u201325%,\u2009&gt;\u200925\u201350%, and\u2009&gt;\u200950% according to doses used in randomized trials. The primary endpoint was all-cause mortality at three years. Secondary endpoints comprised of a composite arrhythmic endpoint (i.e., recurrences of ventricular tachyarrhythmias\u00a0and appropriate ICD therapies) and cardiac rehospitalization. Kaplan\u2013Meier survival curves and multivariable Cox regression analyses were applied for statistics. A total of\u00a01313 patients with BB were included; most patients were discharged with\u2009&gt;\u200925\u201350% of BB target dose (59%). At three years, &gt;\u200912.5\u201325% of BB target dose was associated with improved long-term mortality as compared to the\u2009&gt;\u20090\u201312.5% group (HR\u2009=\u20090.489; 95% CI 0.297\u20130.806; <jats:italic>p<\/jats:italic>\u2009=\u20090.005), whereas higher BB doses did not improve survival (&gt;\u200925\u201350%: HR\u2009=\u20090.849; <jats:italic>p<\/jats:italic>\u2009=\u20090.434;\u2009&gt;\u200950%: HR\u2009=\u20090.735; <jats:italic>p<\/jats:italic>\u2009=\u20090.285). In contrast, the composite endpoint and risk of rehospitalization were not affected by BB target dose.\u00a0In conclusion, &gt;\u200912.5\u201325% of BB target dose is associated with best long-term survival among patients with ventricular tachyarrhythmias. In contrast, risk of the composite arrhythmic endpoint and risk of cardiac rehospitalization were not affected by BB dose.<\/jats:p>","DOI":"10.1007\/s00380-021-02018-3","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T13:11:09Z","timestamp":1643029869000},"page":"1213-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-7617","authenticated-orcid":false,"given":"Tobias","family":"Schupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevil","family":"Ziyadova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf Ugur","family":"Sag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"von Zworowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abumayyaleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kambis","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed L.","family":"Abba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Behnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"9169","key":"2018_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Merit-HF Study Group","year":"1999","unstructured":"Merit-HF Study Group (1999) Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001\u20132007","journal-title":"Lancet"},{"issue":"9146","key":"2018_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CI Investigators","year":"1999","unstructured":"Investigators CI (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353(9146):9\u201313","journal-title":"Lancet"},{"issue":"17","key":"2018_CR3","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106(17):2194\u20132199","journal-title":"Circulation"},{"issue":"41","key":"2018_CR4","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 36(41):2793\u20132867","journal-title":"Eur Heart J"},{"issue":"4","key":"2018_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10557-018-6812-z","volume":"32","author":"T Schupp","year":"2018","unstructured":"Schupp T, Behnes M, Wei\u00df C, Nienaber C, Lang S, Reiser L, Bollow A, Taton G, Reichelt T, Ellguth D, Engelke N, Ansari U, El-Battrawy I, Bertsch T, Akin M, Mashayekhi K, Borggrefe M, Akin I (2018) Beta-blockers and ACE inhibitors are associated with improved survival secondary to ventricular tachyarrhythmia. Cardiovasc Drugs Ther 32(4):353\u2013363","journal-title":"Cardiovasc Drugs Ther"},{"issue":"19","key":"2018_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.jacc.2013.04.102","volume":"62","author":"SV Arnold","year":"2013","unstructured":"Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, Dodson JA, Chan PS (2013) Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol 62(19):1791\u20131801","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2018_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ahj.2010.06.023","volume":"160","author":"JJ Goldberger","year":"2010","unstructured":"Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O\u2019Rourke R, Shah PK, Smith SC Jr (2010) beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J 160(3):435\u201342.e1","journal-title":"Am Heart J"},{"issue":"11","key":"2018_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","volume":"150","author":"FA McAlister","year":"2009","unstructured":"McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784\u2013794","journal-title":"Ann Intern Med"},{"issue":"3","key":"2018_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, B\u00f6hm M, Anker SD, Thompson SG, Poole-Wilson PA (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215\u2013225","journal-title":"Eur Heart J"},{"issue":"13","key":"2018_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","volume":"66","author":"JJ Goldberger","year":"2015","unstructured":"Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, Smith SC Jr, Suba\u010dius H (2015) Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol 66(13):1431\u20131441","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"2018_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors\/Task Force M (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"issue":"38","key":"2018_CR12","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Group ESCSD (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893\u20132962","journal-title":"Eur Heart J"},{"issue":"10","key":"2018_CR13","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"SM Al-Khatib","year":"2017","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL (2017) 2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 15(10):e190\u2013e252","journal-title":"Heart Rhythm"},{"issue":"3","key":"2018_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","volume":"6","author":"GROUP TMTR","year":"1985","unstructured":"GROUP TMTR (1985) Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 6(3):199\u2013226","journal-title":"Eur Heart J"},{"issue":"8251","key":"2018_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","volume":"318","author":"\u00c5 Hjalmarson","year":"1981","unstructured":"Hjalmarson \u00c5, Herlitz J, M\u00e1lek I, Ryd\u00e9n L, Vedin A, Waldenstr\u00f6m A, Wedel H, Elmfeldt D, Holmberg S, Nyberg G, Swedberg K, Waagstein F, Waldenstr\u00f6m J, Wilhelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 318(8251):823\u2013827","journal-title":"Lancet"},{"issue":"9266","key":"2018_CR16","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"C Investigators","year":"2001","unstructured":"Investigators C (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357(9266):1385\u20131390","journal-title":"Lancet"},{"issue":"2","key":"2018_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0002-9149(02)03098-9","volume":"91","author":"R Lampert","year":"2003","unstructured":"Lampert R, Ickovics JR, Viscoli CJ, Horwitz RI, Lee FA (2003) Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the Beta-Blocker Heart Attack Trial. Am J Cardiol 91(2):137\u2013142","journal-title":"Am J Cardiol"},{"issue":"10","key":"2018_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","volume":"15","author":"AP Maggioni","year":"2013","unstructured":"Maggioni AP, Anker SD, Dahlstr\u00f6m U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15(10):1173\u20131184","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2018_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","volume":"60","author":"M Fiuzat","year":"2012","unstructured":"Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Pi\u00f1a IL, Whellan D, O\u2019Connor CM (2012) Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol 60(3):208\u2013215","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2018_CR20","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1093\/eurheartj\/ehi386","volume":"26","author":"M Metra","year":"2005","unstructured":"Metra M, Torp-Pedersen C, Swedberg K, Cleland JGF, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA, investigators ftC (2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26(21):2259\u20132268","journal-title":"Eur Heart J"},{"issue":"1","key":"2018_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/ehjqcco\/qcx031","volume":"4","author":"C Bredy","year":"2018","unstructured":"Bredy C, Ministeri M, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Diller GP, Gatzoulis MA, Dimopoulos K (2018) New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes 4(1):51\u201358","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-021-02018-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00380-021-02018-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-021-02018-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T04:04:40Z","timestamp":1653624280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00380-021-02018-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1007\/s00380-021-02018-3","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"type":"print","value":"0910-8327"},{"type":"electronic","value":"1615-2573"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"25 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}